CIK 0001410098
- Non-accelerated filer
CorMedix Inc.
Sign in to watch- Ticker
- CRMD
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 908-517-9500
- Business address
- 389 INTERPACE PKWY, SUITE 450, PARSIPPANY, NJ, 07054
- Open-market buys, last 90 days
- $391,200
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$391,200. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-01-14 | Costa Paulo F Director | Grant or award · Stock Option (Right to Buy Common Stock) | +20,000 | 20,000 | ||
| 2022-11-15 | Todisco Joseph Chief Executive Officer | Purchase | +20,000 | $3.82 | $76K | 242,169 |
| 2022-08-24 | Todisco Joseph Chief Executive Officer | Purchase | +4,700 | $3.92 | $18K | 222,169 |
| 2022-05-17 | Kaplan Myron Director | Purchase | +5,000 | $3.78 | $19K | 160,034 |
| 2022-05-16 | Todisco Joseph Chief Executive Officer | Purchase | +10,000 | $3.38 | $34K | 217,469 |
| 2022-05-10 | Todisco Joseph Chief Executive Officer | Grant or award | +207,469 | 207,469 | ||
| 2022-05-10 | Todisco Joseph Chief Executive Officer | Grant or award · Stock Option (Right to Buy Common Stock) | +500,000 | 500,000 | ||
| 2022-02-22 | Costa Paulo F Director | Grant or award · Stock Option (Right to Buy Common Stock) | +20,000 | 20,000 | ||
| 2022-02-22 | Duncan Gregory Scott Director | Grant or award · Stock Option (Right to Buy Common Stock) | +20,000 | 20,000 | ||
| 2022-02-22 | DUNTON ALAN W Director | Grant or award · Stock Option (Right to Buy Common Stock) | +20,000 | 20,000 | ||
| 2022-02-22 | Lefkowitz Steven W Director | Grant or award · Stock Option (Right to Buy Common Stock) | +20,000 | 20,000 | ||
| 2022-02-22 | Kaplan Myron Director | Grant or award · Stock Option (Right to Buy Common Stock) | +20,000 | 20,000 | ||
| 2022-02-22 | Dillione Janet Director | Grant or award · Stock Option (Right to Buy Common Stock) | +20,000 | 20,000 | ||
| 2022-02-18 | Nusbickel Thomas EVP, Chief Commercial Officer | Grant or award · Stock Option (Right to Buy Common Stock) | +100,000 | 100,000 | ||
| 2022-02-18 | Masson-Hurlburt Elizabeth EVP, Head of Clinical Ops. | Grant or award · Stock Option (Right to Buy Common Stock) | +100,000 | 100,000 | ||
| 2022-02-18 | Mounts Phoebe General Counsel | Grant or award · Stock Option (Right to Buy) | +140,000 | 140,000 | ||
| 2022-02-18 | David Matthew T Interim CEO and CFO | Grant or award · Stock Option (Right to Buy Common Stock) | +0 | 100,000 | ||
| 2021-12-27 | Kaplan Myron Director | Gift | −20,000 | 155,034 | ||
| 2021-12-27 | Kaplan Myron Director | Gift | −5,000 | 150,034 | ||
| 2021-12-27 | Kaplan Myron Director | Gift | −5,000 | 145,034 |
Page 10 of 16 · 301 trades